Research ArticleCancer

ctDNA monitoring using patient-specific sequencing and integration of variant reads

See allHide authors and affiliations

Science Translational Medicine  17 Jun 2020:
Vol. 12, Issue 548, eaaz8084
DOI: 10.1126/scitranslmed.aaz8084

Article Information

vol. 12 no. 548

Print ISSN: 
Online ISSN: 
  • Received for publication October 10, 2019
  • Resubmitted February 10, 2020
  • Accepted for publication May 28, 2020
  • .

Author Information

  1. Jonathan C. M. Wan1,2,*,,
  2. Katrin Heider1,2,*,
  3. Davina Gale1,2,
  4. Suzanne Murphy1,2,3,
  5. Eyal Fisher1,2,
  6. Florent Mouliere1,2,4,
  7. Andrea Ruiz-Valdepenas1,2,
  8. Angela Santonja1,2,
  9. James Morris1,2,
  10. Dineika Chandrananda1,2,,
  11. Andrea Marshall5,
  12. Andrew B. Gill2,3,6,
  13. Pui Ying Chan1,2,
  14. Emily Barker7,
  15. Gemma Young7,
  16. Wendy N. Cooper1,2,
  17. Irena Hudecova1,2,
  18. Francesco Marass1,2,§,
  19. Richard Mair1,2,8,
  20. Kevin M. Brindle1,2,9,
  21. Grant D. Stewart2,3,10,
  22. Jean E. Abraham11,12,
  23. Carlos Caldas1,2,11,
  24. Doris M. Rassl2,13,
  25. Robert C. Rintoul2,13,14,
  26. Constantine Alifrangis15,
  27. Mark R. Middleton16,
  28. Ferdia A. Gallagher2,3,4,
  29. Christine Parkinson3,
  30. Amer Durrani3,
  31. Ultan McDermott15,||,
  32. Christopher G. Smith1,2,
  33. Charles Massie1,2,14,,
  34. Pippa G. Corrie3,2, and
  35. Nitzan Rosenfeld1,2,,#
  1. 1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
  2. 2Cancer Research UK Major Centre—Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
  3. 3Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
  4. 4Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
  5. 5Warwick Clinical Trials Unit, University of Warwick, Coventry CV4 7AL, UK.
  6. 6Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
  7. 7Cambridge Clinical Trials Unit—Cancer Theme, Cambridge CB2 0QQ, UK.
  8. 8Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
  9. 9Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK.
  10. 10Department of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK.
  11. 11Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK.
  12. 12Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK.
  13. 13Royal Papworth Hospital NHS Foundation Trust, Cambridge CB2 0AY, UK.
  14. 14Department of Oncology, University of Cambridge Hutchison–MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK.
  15. 15Wellcome Sanger Institute, Hinxton CB10 1SA, UK.
  16. 16National Institute for Health Research Biomedical Research Centre, Oxford OX4 2PG, UK.
  1. #Corresponding author. Email: nitzan.rosenfeld{at}
  • * These authors contributed equally to this work.

  • Present address: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

  • Present address: Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia.

  • § Present address: Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland.

  • || Present address: AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK.

  • These authors jointly supervised this work.


Article usage

Article usage: June 2020 to April 2021

Jun 202078761491672
Jul 20201144235167
Aug 202054211666
Sep 2020579221134
Oct 202054410657
Nov 2020549181114
Dec 2020325168106
Jan 202144210776
Feb 202142810272
Mar 202144111275
Apr 20212265932

Stay Connected to Science Translational Medicine